I haven’t read the book but it sounds like a little sensationalism might have crept in somehow. I trust my memory of what I read in the scientific and lay press (i.e., Time magazine) as well as conversations with Folkman and many other scientists over the past 30 years.
“You’re a surgeon, what the hell do you know about cancer?” to “You greedy bastard with your corporate partnerships! If I recall, some even described his work as “dangerous” since it diverted funds from “real” cancer research.”
If the work of every scientist criticized this way is “pseudoscience” then nearly everything is or was pseudoscience.
“As I recall, the blood supply-cancer connection first occurred to Folkman in the late fifties/early sixties (which is not to say nobody had ever thought of the same thing before) and conducted work all throughout the sixties while not performing surgical duties.”
IIRC, Folkman says that he got the idea from his work as a surgeon. I think he did some research on perfusion solutions to keep kidneys viable between harvest and transplantation and in the course of that was impressed with the need for perfusion to retain viability. I know he published on perfusion of the thyroid. I forget the details of this early work but it led to his work on angiogenesis factors. BTW, he’s a clever guy and an imaginative researcher. (One paper he published was how to measure blood oxyegen concentration (this was when such measurements had to be done with equipment that was not widely available) by sucking blood into an syringe filled with acrylamide and a bead. IIRC, you turned the syringe end over end waiting for the bead to stop moving. The bead stopped moving when the acrylamide polymerized and the speed with whidh the acyrlamide polymerized was proportional to the oxygen content. Cute.
“The fact that he had a huge lab was (again, as I recall) basically a perk for being chief pediatric surgeon at Boston Children’s.”
A big desk and some kind of lab I believe. But a large lab WITH postdocs to work in it comes with grant money, not with the title of chief surgeon.
“Nevertheless, this sort of partnership is an common and important source of research funds today. Perhaps ironically, some now view the opportunity to do research in an big-name industry-funded lab as a sign of prestige rather than of selling out.”
Indeed, things have changed greatly. Whether this is all good or not is open to question.
“I see Folkman’s decision to get involved in industry-funding as equal parts despiration for funding (hard to secure for cancer research outside the mainstream)”
Please ask someone who does cancer research IN the mainstream if it is not hard to secure funding.
“as it seemed that Folkman didn’t care how a cure was discovered or who made it or even who profited from it. just so long as it was found.”
Is it your intention to malign all those cancer researchers who are not Judah Folkman?
“This practicality and perhaps a bit of naivety has caused him to go against the academian ethos in other ways as well, including speaking to the media.”
There is nothing naive about Judah Folkman and nothing unusual about scientists who blow there own horn in the lay press. But scientists who do get good press tend to annoy their colleagues (whether the good press is justified or not). Science is a very competetive business.
“If receiving papers back from a peer-review journal because the reviewers believed that his results didn’t support his findings [sic] is not the same as having his research called pseudo-science, its pretty darn close.”
That is an interesting point of view. I have refereed several papers in which I felt the authors’ results did not support their conclusions and I can’t think of a single case in which I thought that the work was pseudoscience. In my experience, it has been, each time, just a matter of the results not supporting the conclusions.